CLEW News
23 articles/PRNewswire/ -- CLEW, a leading provider of AI-driven clinical surveillance solutions, today announced the launch of its Sepsis Virtual Unit (SVU), designed to...
AvaSure Teams Up with CLEW Medical to Boost High-Acuity Care with AI-Driven Virtual Surveillance
CLEW Expands Its Intelligent Clinical Surveillance Platform to All Inpatient Settings
New Study Finds AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration and Significantly Reduce False Alarms for Clinicians
growth-positive
CLEW announces appointment of Paul Roscoe as CEO
CLEW, a provider of real-time AI analytics platforms for healthcare, has appointed Paul Roscoe as its new CEO. This appointment signals a major expansion in the US and European healthcare markets. CLEW has recently deployed its Virtual ICU platform at major US healthcare systems and created a European sales center. Gal Salomon, the current CEO and co-founder, will become Executive Chairman. The Virtual ICU platform, which has received FDA clearance, uses AI technology to identify patients at risk of deterioration and improve workflow in healthcare systems. Roscoe brings extensive experience in building and scaling organizations in the healthcare industry. CLEW aims to improve clinical outcomes, lower costs, and enhance the provider, patient, and family experience.
CustomersPartners
growth-positive
Penn State Health to Pioneer Next-Generation Virtual ICUs with CLEW Medical's AI Powered Cloud-based Platform
Penn State Health has executed an agreement to offer virtual intensive care units (vICU) using CLEW Medicals tele-ICU platform. The new service is expected to be live in late September and will initially cover 174 adult ICU and intermediate care beds. The COVID-19 pandemic has led to increased demand for critical care beds and burnout among ICU clinicians. The vICU service will help manage capacity and address provider shortages. Penn State Health plans to expand the service to additional facilities in their system and other hospitals and health systems. The use of CLEWs AI technology aims to improve clinical outcomes, lower costs, and enhance the provider, patient, and family experience.
CustomersExpand
growth-positive
Equum and CLEW join forces on telehealth services in acute critical care
Equum Medical has partnered with CLEW Medical to add their cloud-based Tele-ICU platform to its ecosystem of technology partners. The partnership aims to improve clinician efficiency in providing intensive care, especially in light of rising patient acuity and staffing shortages due to the pandemic. CLEW ICU utilizes advanced AI technology to predict patient deterioration and streamline workflow. Equum is a physician-led acute care telehealth company that brings critical care resources to hospitals and healthcare systems. The partnership with CLEW is part of Equums efforts to deliver high-quality tele-critical care services. The article highlights the need for advanced clinical technology in delivering safe and high-quality care, especially in the face of workforce challenges. Equum continues to build its Partner Ecosystem to enhance care delivery.
PartnersCustomers
growth-positive
CLEW Medical Receives FDA Clearance for AI-Based Predictive Analytics Technology to Support Adult ICU Patient Assessment
CLEW Medical has received FDA clearance for its AI-powered ICU solution, CLEWICU, to predict hemodynamic instability in adult patients. This clearance follows the FDAs Emergency Use Authorization for CLEWICUs respiratory deterioration model granted in June 2020. The COVID-19 pandemic has highlighted the need for quick and accurate decision-making in intensive care units, and CLEWICU aims to provide comprehensive, predictive data to help medical professionals identify patients at risk. The system continuously monitors and categorizes patient risk levels, providing clinicians with physiological insight and enabling early evaluation and intervention. CLEWICU uses AI-based algorithms and machine-learning models to analyze patient data and provide calculated insights and notifications. The FDA clearance is a significant milestone for CLEW Medical and the healthcare industry.
CustomersPartners
growth-positive
Predictive analytics takes center stage in the fight against Covid-19 and the critically ill
The article discusses the vulnerabilities in healthcare systems exposed by the Covid-19 pandemic. It highlights the challenges faced by ICUs, including resource limitations, infection control, and protection of healthcare workers. The use of real-time prediction models is proposed as a potential solution to enhance efficiency and resource planning. The article also mentions the need for increased ICU surge capacity and the redeployment of resources. Tele Critical Care is identified as a beneficial tool to expand the reach of critical care experts. Early identification of patient deterioration and planning accordingly is emphasized. The article concludes by stating that the pandemic has accelerated the implementation of technologies to improve patient care and support medical teams. The CEO of Clew Medical, Gal Salomon, provides insights throughout the article.
CustomersPartners
growth-positive
With FDA approval in hand and Covid-19 as a test case, Israel's Clew is ready for its money time
Israeli startup Clew Medical has received FDA authorization for its AI-powered device that provides early identification of respiratory failure and hemodynamic instability in Covid-19 patients. The company, which raised $10 million in a series B funding round led by Pitango Venture Capital, has been working on its AI and machine learning technology since 2015. The FDA approval allows Clew to begin selling its product commercially. Clews technology uses mathematical models to predict patient deterioration up to eight hours in advance, providing early intervention for better outcomes. The company plans to expand its workforce and is also working on a new product called Control Tower, which aims to analyze the entire hospital and provide recommendations for clinical operations.
InvestmentExpand
growth-positive
Predictive care startup Clew gets emergency FDA approval to help treat Covid-19 patients
Clew Medical Ltd., an Israeli startup, has received emergency use authorization from the FDA for its predictive care technology. The technology uses artificial intelligence to detect life-threatening complications in patients in intensive care units, including those with COVID-19. Clews system can assist medical teams in remotely identifying patients who are likely to experience common coronavirus complications, such as respiratory failure and hemodynamic instability. The system also allows for remote patient monitoring, reducing the risk of exposure to infectious diseases. Clew previously raised $20 million in funding, with Pitango Health as one of its main backers.
Investment
growth-positive
FDA greenlights ICU AI for predicting fatal COVID-19 complications - TMG Pulse
The FDA has granted emergency authorization to CLEW Medicals remote data monitoring system, which uses AI software to predict and identify COVID-19 patients at risk for respiratory failure or insufficient blood flow. The system ingests patient data from electronic medical records and medical devices, providing real-time risk classification and alerts to healthcare providers. The FDA believes this system can improve patient care and reduce strain on ICU personnel. CLEW Medical has previously conducted validation studies and has submitted an application for full FDA clearance. The system is currently being tested at tele-ICU facilities in Massachusetts and North Carolina.
Customers
https://www.jpost.com/Opinion/HILLELS-TECH-CORNER-Clues-to-the-COVID-19-mystery-624190
growth-positive
Leading Israeli Hospitals Launch CLEW AI-based TeleICU to Support COVID-19 Crisis
CLEWs TeleICU solution, CLEW-ICU, is being deployed by Tel Aviv Sourasky Medical Center and Sheba Medical Center to manage and treat COVID-19 patients. The solution uses telemedicine technologies and AI-based predictive analytics to expand ICU capacity and resources. It can identify respiratory deterioration in advance and provide real-time acuity classification, allowing timely interventions and improved prognosis. CLEW is also testing the system in the U.S. and has submitted an application for FDA approval. The company aims to provide a meaningful contribution to healthcare providers during the COVID-19 pandemic.
CustomersPartners
growth-positive
Predictive Care Startup Clew Raises $10 Million
Clew Medical Ltd., a predictive care startup, has raised $10 million in a series B funding round led by Pitango Venture Capital. The funding round also saw participation from Relyens, Agate Medical Investments, and Rhön-Klinikum AG. Clew develops an artificial intelligence-based analytics service and mobile app for the early detection of life-threatening complications in patients in intensive care units. The company has raised a total of $20 million to date.
Investment
growth-positive
CLEW to be featured in a new episode of "Information Matrix", with Laurence Fishburne
The article discusses the use of AI-Machine Learning technology developed by CLEW in the treatment of critically ill patients. The integration of CLEWs predictive technology in TeleICUs allows for proactive and predictive assessment, a more collaborative team approach, and efficient clinical resource allocation. The article highlights the need for advanced technologies in critical care units and the potential of AI-Machine Learning to convert electronic medical records into life-saving medical knowledge. The impact on the company is growth-positive. The key theme of the article is the application of AI-Machine Learning in healthcare. The key issues discussed are partnerships and customers. The date of the event described in the article is July 2, 2019. The confidence level is 8.
PartnersCustomers
growth-positive
Israeli clinical analytics co Clew raising $20m
Israeli clinical analytics company Clew is in the final stages of raising $20 million and has signed an agreement with Sheba Medical Center. Clew has developed an analytics platform for predicting life-threatening complications in intensive care. The platform collects data on blood pressure, oxygen levels, and heart capacity to identify patterns of collapse in patients. Clews product has been used in trials at hospitals in Tel Aviv and the US, and hopes to be available as a product next year. The company has raised $10.5 million to date and plans to double its workforce.
InvestmentExpand
growth-positive
Saving lives in the ICU through artificial intelligence
Clew Medical, an Israeli startup, has developed software that uses artificial intelligence (AI) to predict which patients in a hospitals intensive care unit (ICU) are at the highest risk of imminent deterioration. The software connects to the ICUs systems and analyzes data from a patients electronic medical record to predict their trajectory more accurately than doctors or nurses. Clews software can also assist with resource management in the ICU. The company has been in proof-of-concept testing at hospitals in Israel and the United States and is seeking FDA clearance. Clew has raised over $10 million and is looking to raise an additional $20 million in 2018 to expand its reach and improve its cloud-based system.
CustomersInvestment
growth-positive
Microsoft CEO Meets Winners of Calcalist's Startup Contest
Clew Medical, an Israel-based start-up that uses artificial intelligence to help intensive care units reduce treatment time and costs, has visited Microsofts headquarters in Seattle. The visit was part of a delegation of 30 start-ups led by Shelly Landsmann, the general manager of Microsoft’s operations in Israel. During the visit, the delegation met with senior executives at Microsoft’s research and development center, learned about the company’s vision in the areas of artificial intelligence, big data, and cybersecurity, and presented their ventures to Microsoft representatives.
Partners
growth-positive
Clew Medical launches AI analytics platform
Israeli AI analytics company Clew Medical has launched its AI predictive-analytics platform to prevent life threatening complications in all care settings. The company has raised $10.5 million to date and is now looking to raise $20 million in the next few months. Clew Medicals platform provides medical staff and healthcare administrators with actionable insights to streamline medical care.
Investment
growth-positive
Intensix Raises $8.3 Million in Series A, Funding Led by Pitango Venture Capital
Intensix, a developer of a real-time predictive analytics platform for early detection of patient deterioration in hospitals, has completed an $8.3 million Series A financing round led by Pitango Venture Capital. The funds will be used to boost the companys sales and marketing operations in North America and to expand and accelerate the development of its predictive analytics platform. Intensixs platform applies machine learning to provide accurate predictive clinical analytics that can help ICU and high-acuity staff and management avoid deteriorations and save lives. The company aims to improve clinical outcomes, reduce hospital costs, and increase revenue sources. Ittai Harel, Managing General Partner at Pitango, will join Intensixs Board of Directors.
Investment
growth-positive
Has an Israeli start-up solved the mystery of sepsis?
Israeli big data medical research company Intensix has conducted a study on the causes of dangers in intensive care units (ICUs) in hospitals. The study aims to shed light on why ICUs, despite having the highest ratio of doctors and nurses to patients and a large amount of resources, have the worst patient outcomes. Intensix plans to utilize its database of over 600 billion pieces of patient data to analyze patient conditions in real time and provide alerts to doctors and nurses of impending medical problems like sepsis. The companys system, which is installed in hospitals, will constantly monitor patients vital signs and other factors to determine if they need extra help. The study is expected to significantly lower the casualty rate in ICUs and improve patient care.
Customers
growth-positive
Big data co Intensix and Ichilov to collaborate
Israeli startup Intensix has announced a research collaboration with Sourasky Medical Center to develop a system for early detection of complications in intensive care patients. The collaboration involves conducting research based on data from approximately 8,000 patients hospitalized in the ICU between 2007 and 2014. Intensix has installed a system at the hospital to alert clinicians of possible complications. The system will analyze real-time data streams from medical devices and electronic health records to provide immediate insights on patient conditions. The goal is to improve critical decision-making and provide tailored treatment to each patient. Intensix aims to reduce mortality and morbidity in intensive care units. The company was founded in 2015 and its mission is to provide predictive clinical analytics for healthcare providers.
Customers
